{
    "clinical_study": {
        "@rank": "73842", 
        "arm_group": {
            "arm_group_label": "Rituximab, MTX, folic acid", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single-arm, multicenter, efficacy, and safety maintenance study of\n      the Phase 1 Study CT-P10 1.1. This study is designed to assess the long-term efficacy and\n      safety of CT-P10 co-administered with MTX  and folic acid  in patients with RA who have\n      completed the scheduled visits in Study CT-P10 1.1"
        }, 
        "brief_title": "Long-Term Efficacy and Safety of CT-P10 in Patients With RA", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has disease improvement (moderate or good response) according to Disease\n             Activity Score using 28 joint counts (DAS28) during the last course of treatment in\n             Study CT-P10 1.1.\n\n          -  Patient has completed all of the scheduled visits in the Study CT-P10 1.1 Main Study\n             Period, including the Core Study Period and/or Extension Study Period.\n\n        Exclusion Criteria:\n\n          -  Patient has been withdrawn from Study CT-P10 1.1 for any reason.\n\n          -  Patient has, at the time of providing informed consent, any current medical issues\n             such as serious adverse events (SAEs) or current or previous intolerance issues that\n             mean continuation in this maintenance study could be detrimental to their health, in\n             the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873443", 
            "org_study_id": "CT-P10 1.3", 
            "secondary_id": "2012-005502-21"
        }, 
        "intervention": {
            "arm_group_label": "Rituximab, MTX, folic acid", 
            "description": "Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week", 
            "intervention_name": "Rituximab, MTX, folic acid", 
            "intervention_type": "Drug", 
            "other_name": "Rituximab=CT-P10"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Incheon", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Inha University College of Medicine Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1", 
        "overall_official": {
            "affiliation": "Hanyang University", 
            "last_name": "DaeHyun Yoo, Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy will be assessed by evaluation of ACR criteria (ACR 20% , ACR 50% , ACR 70%, and hybrid ACR response), Safety will be assessed by evaluation of hypersensitivity monitoring via vital sign measurements (including blood pressure, heart and respiratory rates, and body temperature),etc,.", 
            "measure": "Efficacy evaluation by ACR criteria and safety evaluation by hypersensitivity monitoring", 
            "safety_issue": "Yes", 
            "time_frame": "8 week interval"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873443"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Celltrion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celltrion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}